|  |  |  |  |
| --- | --- | --- | --- |
|  | **OR****(n = 68)** | **Office****(n = 37)** | **P-value** |
| 6-month treatment outcome Treatment failure Retreatment | 23 (33.8%)16 (23.5%) | 13 (35.1%)9 (24.3%) | p > 0.999p > 0.999 |
| 12-month treatment outcome Treatment failure Retreatment | 17 (50.0%)10 (29.4%) | 9 (37.5%)7 (28.0%) | p = 0.426p > 0.999 |
| Post-procedure urinary retentiona | 11 (16.4%) | 1 (2.7%) | p = 0.052 |
| Post-procedure UTI UTI treatment Culture-proven | 12 (17.9%)7 (10.5%) | 5 (13.5%)3 (8.1%) | p = 0.783p > 0.999 |
| Retreatment for SUI Urethral bulking Pelvic floor physical therapy Pessary Midurethral sling | 12 (19.1%)1 (1.5%)1 (1.5%)7 (10.3%) | 3 (8.1%)4 (10.8%)0 (0%)3 (8.1%) | p = 0.164p = 0.051p > 0.999p > 0.999 |
| Anesthesia during procedure Local Sedation General | 2 (2.9%)58 (85.3%)8 (11.8%) | 37 (100%)0 (0%)0 (0%) | **p < 0.001** |
| Antibiotic prophylaxis during procedure Cefoxitin Cefazolin Nitrofurantoin Other None | 54 (80.6%)10 (14.9%)0 (0%)1 (1.5%)2 (3.0%) | 0 (0%)0 (0%)7 (18.9%)4 (10.8%)26 (70.3%) | **p < 0.001** |
| Phenazopyridine during procedure | 4 (5.9%) | 5 (13.5%) | p = 0.27 |
| PAH injection volume, mL | 2 (2 – 2) | 2 (1.6 – 2) | **p < 0.05** |
| Cough stress test performed during procedure | 8 (11.8%) | 19 (57.6%) | **p < 0.001** |
| Procedure aborted | 0 (0%) | 4 (10.8%) | **p < 0.05** |
| Concurrent procedures Intravesical onabotulinum toxin A  Pelvic floor muscle injections Pelvic organ prolapse surgery Other surgeryb | 14 (20.6%)3 (4.4%)4 (5.9%)7 (10.3%) | 6 (16.2%)0 (0%)0 (0%)0 (0%) | p = 0.80p = 0.55p = 0.30p = 0.05 |
| Surgeon Surgeon A Surgeon B Surgeon C Surgeon D Surgeon E Surgeon F Surgeon G Surgeon H Surgeon I | 9 (13.2%)7 (10.3%)0 (0%)6 (8.8%)20 (29.1%)5 (7.4%)2 (2.94%)12 (17.7%)7 (10.3%) | 3 (8.1%)5 (13.5%)3 (8.1%)3 (8.1%)11 (29.7%)10 (27.0%)1 (2.7%)0 (0%)1 (2.7%) | **p < 0.01** |

a As documented by history.

b Includes hysterectomy for non-prolapse indication, excision of endometriotic implants, hymenectomy, mesh excision, and bladder instillations.

PAH, polyacrylamide hydrogel; SUI, stress urinary incontinence; UTI, urinary tract infection